Objective To investigate the efficacy of terlipressin and double- dose octreotide in reducing hepatic venous pressure gradient( HVPG) in patients with liver cirrhosis. Methods A total of 41 patients who were diagnosed with liver cirrhosis and esophageal and gastric varices in our hospital from June 2014 to March 2015 were randomly divided into terlipressin group( group A,22 patients) and octreotide group( group B,19 patients). The patients in group A were given intravenous injection of terlipressin 2 mg,and those in group B were given intravenous injection of octreotide 100 μg followed by intravenous infusion of the same drug at 50 μg / h. HVPG was measured before administration and at 10,20,and 30 min after administration,and the reduction in HVPG and changes in blood pressure and heart rate after administration were observed. The t- test was applied for comparison of continuous data between groups,and the chi- square test or Fisher's exact test was applied for comparison of categorical data between groups. Results In group A,HVPG before administration and at 10,20,and 30 min after administration was 18. 86 ± 5. 66,16. 75 ± 5. 54,16. 14 ± 5. 43,and 15. 25 ± 5. 93 mm Hg,respectively,while in group B,HVPG at the above time points was 19. 91 ± 6. 68,16. 58 ± 5. 86,17. 03 ± 6. 14,and 17. 66 ± 6. 09 mm Hg,respectively; each group showed a significant change in HPVG at each time point after administration compared with that before administration( t = 4. 010,6. 413,5. 134,5. 533,5. 741,and 4. 017,all P < 0. 05),while the reduction in HVPG after administration showed no significant differences across the two groups. The patients in both groups experienced varying degrees of reduction in heart rate and increase in blood pressure.Group A had a significantly larger reduction in heart rate compared with group B( 16. 13% ± 9. 28% vs 3. 35% ± 6. 34%; t =- 5. 062,P < 0. 001); group A had a significantly larger increase in blood pressure compared with group B( 17. 06 ± 8. 11% vs 11. 70 ± 7. 76%; t =2. 178,P = 0. 037). Conclusion Terlipressin and double- dose octreotide can effectively reduce HVPG in patients with liver cirrhosis and esophageal and gastric varices. Terlipressin can reduce HVPG more obviously over time,but terlipressin has a greater influence on heart rate and blood pressure.
按照UDCA治疗应答情况，637例患者中436例发生完全应答，201例为应答不良。性别分布中，完全应答组与应答不良组分布无统计学意义(P值均＞0.05)，基线存在肝硬化的患者UDCA应答率更高(78.9% vs 71.1%，P=0.032)，生化指标中，TBil、AST、ALP、TBA和TC在两组间存在统计学差异(P值均＜0.001)。免疫指标中，应答不良组IgA、IgM水平及抗Gp210阳性率均较高(P值均＜0.05)。预后风险评分中，应答不良组MRS、Globe评分、UK-PBC评分均高于完全应答组(P值均＜0.001)(表 2)。
表
2
UDCA治疗完全应答与应答不良患者基线指标及风险评分差异
Table
2.
Differences of baseline characteristics and risk scores between PBC with complete response and poor response to UDCA treatment
根据IgM预测UDCA应答不良的最佳临界值将患者分为IgM≥1.5×ULN及IgM＜1.5×ULN两组，性别分布、年龄、肝硬化占比在两组中比较差异均无统计学意义(P值均＞0.05)；IgM≥1.5×ULN组AST、ALP、TC显著高于IgM＜1.5×ULN组(P值均＜0.05)；IgM≥1.5×ULN组IgG水平及抗Gp210阳性率显著高于IgM＜1.5×ULN组(P值均＜0.001)。IgM≥1.5×ULN组经过UDCA治疗后发生应答不良患者显著高于IgM＜1.5×ULN组(38.3% vs 27.1%，P=0.003)(表 5)。
表
5
不同IgM水平PBC患者基线临床特征及UDCA疗效比较
Table
5.
Comparison of baseline characteristics and the outcome of UDCA treatment between PBC with different levels of IgM
UDCA是PBC治疗的一线药物，可显著改善部分PBC患者非肝移植存活率[11-12]，但仍有30%~40%的患者对UDCA治疗无应答，本研究中显示UDCA完全应答率为68.4%，对于这部分患者需要及时联合一种或两种二线药物来改善胆汁淤积以预防疾病进展[13]。UDCA治疗可能影响IgM水平，研究[14]发现UDCA能够显著降低细菌CpG诱导的总IgM和IgM-AMA的产生，但对IgG-AMA的水平却无影响。IgM与肝硬化相关症状和肝脏相关事件的发生关系密切，在UDCA联合苯扎贝特治疗过程中，不论ALP及GGT下降与否，当IgM水平持续异常时，患者的预后均较差，其生存期显著低于IgM水平正常化的患者，治疗过程中IgM水平的逐步正常化可能提示预后较好[15]。对于UDCA不完全应答的PBC患者，在给予联合利妥昔单抗治疗后，IgM水平随着肝功能指标的好转而逐步下降[16]。IgM正常化可作为长期预后的预测指标，但初始IgM正常患者IgM水平的变化情况及预测因素尚缺乏研究。在本研究中，UDCA治疗基线IgM平均水平为2.76 g/L，IgM升高的占比为56.0%，在UDCA完全应答组与应答不良组之间，基线IgM水平存在显著性差异(P=0.034)，进一步分析IgM升高与IgM正常组患者的临床特征及在UDCA治疗1年后的疗效差异，发现IgM正常组UDCA应答率高于IgM升高组(71.8% vs 65.8%)，但两组差异无统计学意义(P=0.108)，通过ROC曲线分析获得IgM预测UDCA治疗1年后应答不良风险的最佳临界值(1.5×ULN)，按最佳临界值进行分组后，结果显示IgM＜1.5×ULN组的PBC患者发生UDCA应答率显著高于IgM≥1.5×ULN组(72.9% vs 61.7%, P=0.003)，IgM≥1.5×ULN组发生UDCA应答不良风险是前者的1.416倍(95%CI: 1.129~1.776)，因此基线IgM水平可能有助于预测PBC治疗应答。
[1]ABRALDES JG,SARLIEVE P,TANDON P,et al.Measurement of portal pressure[J].Clin Liver Dis,2014,18(4):779-792.
[2]LA MURA V,ABRALDES JG,RAFFA S,et al.Prognostic value of acute hemodynamic response to i.v.propranolol in patients with cirrhosis and portal hypertension[J].J Hepatol,2009,51(2):279-287.
[3]SHAH HA,AZAM Z,RAUF J,et al.Carvedilol vs.esophageal variceal band ligation in the primary prophylaxis of variceal hemorrhage:a multicentre randomized controlled trial[J].J Hepatol,2014,60(4):757-764.
[4]XIA YL,ZHANG CQ,WANG GC,et al.Individual and combined effects of octreotide and terlipressin on hepatic venous pressure gradient in cirrhotic patients[J].J Clin Hepatol,2015,31(2):214-218.(in Chinese)夏玉莲,张春清,王广川,等.奥曲肽和特利加压素单用或联用对肝硬化患者肝静脉压力梯度的影响[J].临床肝胆病杂志,2015,31(2):214-218.
[5]de FRANCHIS R,BAVENO VI FACULTY.Expanding consensus in portal hypertension:report of the BavenoⅥConsensus Workshop:stratifying risk and individualizing care for portal hypertension[J].J Hepatol,2015,63(3):743-752.
[6]GARCIA-PAGAN JC.Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy[J].Semin Liver Dis,2008,48(2):229-236.
[7]VILLANUEVA C,PIQUERAS M,ARACIL C,et al.A randomized controlled trial comparing ligation and sclerotherapy as emergency endoscopic treatment added to somatostatin in acute variceal bleeding[J].JHepatol,2006,45(4):560-567.
[8]GARCIA-TSAO G.Effectiveness of combined pharmacologic and ligation therapy in high-risk patients with acute esophageal variceal bleeding[J].AM J Gastroenterol,2011,106(10):1787-1795.
[9]TAKASHIMIZU S,KOJIMA S,NISHIZAKI Y,et al.Effect of endothelin A receptor antagonist on hepatic hemodynamics in cirrhotic rats.Implications for endothelin-1 in portal hypertension[J].Tokal J Exp Clin Med,2011,36(2):37-43.
[10]Cooperative Study Group of Octreotide in China.Efficacy of octreotide in the treatment of acute variceal bleeding in cirrhotic patients:a prospective,multicentric and randomized clinical trial[J].Chin J Dig,2005,25(1):37-40.(in Chinese)奥曲肽全国协作组.两种剂量奥曲肽治疗食管、胃静脉曲张大出血多中心随机对照临床疗效观察[J].中华消化杂志,2005,25(1):37-40.
[11]ESCORSELL A,BANDI JC,ANDREU V,et al.Desensitization to the effects of intravenous octreotide in cirrhotic patients with portal hypertension[J].Gastroenterology,2001,120(1):161-169.
[12]WU Y,CHENG CS.Comparision the effect and safety of terlipressin vs octreotide on treatment of upper gastrointestinal hemorrhage in liver cirrhosis[J].Chin J Clin Gastroenterol,2015,27(1):23-26.(in Chinese)吴燕,程昌盛.特利加压素与奥曲肽治疗肝硬化上消化道出血的效果与安全性比较[J].临床消化病杂志,2015,27(1):23-26.
HAN L, LIANG QS, XIE H, et al. Value of baseline IgM level in predicting the treatment response of primary biliary cholangitis[J]. J Clin Hepatol, 2022, 38(4): 815-820. DOI: 10.3969/j.issn.1001-5256.2022.04.015.
HAN L, LIANG QS, XIE H, et al. Value of baseline IgM level in predicting the treatment response of primary biliary cholangitis[J]. J Clin Hepatol, 2022, 38(4): 815-820. DOI: 10.3969/j.issn.1001-5256.2022.04.015.
下载:
DownLoad: